Trials / Available
AvailableNCT07216378
Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat
On Demand Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With Hereditary Angioedema (HAE) With Sebetralstat
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- KalVista Pharmaceuticals, Ltd. · Industry
- Sex
- All
- Age
- 2 Years – 11 Years
- Healthy volunteers
- —
Summary
The sebetralstat Early Access Program (EAP) provides early access to the investigational medicinal product (IMP) sebetralstat to eligible and approved Hereditary Angioedema (HAE) pediatric (ages 2-11) post-trial and naïve patients for the on-demand treatment of angioedema attacks where the treating Physician determines they might benefit from this treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sebetralstat | Oral Plasma Kallikrein Inhibator |
Timeline
- First posted
- 2025-10-14
- Last updated
- 2026-02-04
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT07216378. Inclusion in this directory is not an endorsement.